Page 91 of 93 FirstFirst ... 4181828384858687888990919293 LastLast
Results 901 to 910 of 927

Thread: Spinal Cord Injury Articles Posted by Manouli

  1. #901
    No One Wants To Hear It, But Geron Has A Stake In Spinal Cord Injury Again
    May. 9.17 | About: Geron Corporation (GERN)
    https://seekingalpha.com/author/zach...n-phd/articles https://seekingalpha.com/author/zach...n-phd/articles
    Zach Hartman, PhD
    Biotech, healthcare, Deep Value, contrarian
    (2,300 followers)
    Summary
    Geron's train is driven almost entirely by imetelstat, and most long-term shareholders seem to want to forget their past regenerative medicine follies.
    But development has continued by BioTime after it sold the assets, and Geron stands to benefit from the approval.
    Promising data from spinal cord injury should be a catalyst to consider that alternative sources of revenue may be possible in the future.
    There was a time when the fate of Geron Corporation (NASDAQ:GERN) rested entirely on its nascent regenerative medicine platform, which was supported by the first ever approval for a stem cell based clinical trial in the US in January 2009.
    read.....
    https://seekingalpha.com/article/407...al-cord-injury

  2. #902
    Senior Member
    Join Date
    Apr 2016
    Location
    Cincinnati, Ohio, USA
    Posts
    1,127
    Geron's stake hasn't changed. They'll get royalties of Asterias' stem cells work as they would've a month ago or a year ago. The only reason it's in the news is some recent pr from the Asterias trials which is tempered by reports (via participants on Facebook) that their increase from 10 million to 20 million cells hasn't resulted in any additional improvements.
    T3-T7 complete since Sept 2015

  3. #903
    Improved blood flow can restore motor function after spinal cord injury, new research reveals
    Study overturns long-held belief that blood supply below injury site naturally returns to normal.
    By Laurie Wang on May 9, 2017

    A new discovery at the University of Alberta will fundamentally alter how spinal cord function and rehabilitation are viewed after spinal cord injuries.
    Neuroscientists found that spinal blood flow was unexpectedly restricted after a spinal cord injury, and that improving blood flow or simply inhaling more oxygen produces lasting improvements in cord oxygenation and motor functions.
    Previous work had shown that while blood flow was temporarily disrupted at the injury site, it resumed rapidly. It was more or less assumed that the blood flow was normal below the injury. This turns out to be wrong.
    “We’ve shown for the first time that a spinal cord injury leads to a chronic state of poor blood flow and lack of oxygen to neuronal networks in the spinal cord,” said co-principal investigator Karim Fouad, professor in the Faculty of Rehabilitation Medicine and Canada Research Chair for spinal cord injury.
    “By elevating oxygen in the spinal cord we can improve function and re-establish activity in different parts of the body.”
    more...

    https://www.ualberta.ca/news-and-eve...search-reveals

  4. #904
    Robotics are helping paralyzed people walk again, but the price tag is huge

    Ashley Barnes was 35 years old when doctors told her she would never walk again.
    A botched spinal procedure in 2014 paralyzed her from the waist down. The Tyler, Tex., resident had been an avid runner, clocking six miles daily when not home with her then-9-year-old autistic son, whom she raised alone. Life in a wheelchair was not an option.
    “I needed to be the best mom I could be,” Barnes said. “I needed to be up and moving.”
    So she threw herself into physical therapy, convinced she would one day run again. Soon she realized that wasn’t a reality.
    Although she wore a brave face, “I would save my moments of crying for my room,” she said.
    more....
    http://www.denverpost.com/2017/06/10...zed-expensive/

  5. #905
    Licensing agreements target spinal cord injury, cancer
    /footer/benefits?tsid=17
    (Ref: UT Health San Antonio)
    June 26th, 2017
    ⦁ UT Health San Antonio and UT Health Houston announced agreements June 23 to grant exclusive global licenses for two unique biologic therapeutics to AlaMab Therapeutics Inc., a subsidiary of CSPC Pharmaceutical Group Ltd. The biologics will be developed into novel, first-in-class therapies for spinal cord injury and breast cancer bone metastasis.

    read...
    https://www.firstwordpharma.com/node/1483435

  6. #906
    New surgery may offer treatment for spinal injuries

    By: Emily Lunardo | General Health | Wednesday, August 02, 2017 - 05:30 AM

    The spinal cord makes up a key part of the body’s motor and nervous systems. It is what relays communications between neurons in our muscles and neurons in the brain, ultimately controlling muscle movements. It also delivers sensory information regarding pain, temperature, and touch between the brain and other body parts.

    This is why spinal cord injuries are so inhibiting. Where motor neurons connect with the spinal cord, they form what is known as the motor root (this is called the sensory root for sensory neurons), which is essentially a clump or knot of neurons surrounding the site of attachment. When traumatic injuries occur to the spine, these roots are often torn, causing the patient to lose neuron function in those areas. Scientists have spent years researching treatments for these injuries that may help patients recover some of the functions provided by the spinal cord.

    read...

    http://www.belmarrahealth.com/new-su...inal-injuries/

    Reply Reply to All Forward More

  7. #907
    It’s Not a Rat’s Race for Human Stem Cells Grafted to Repair Spinal Cord Injuries
    Lengthy study finds that implanted neural stem cells grow slow and steady, and success needs to be measured accordingly
    August 28, 2017 | Scott LaFee

    ​More than one-and-a-half years after implantation, researchers at University of California San Diego School of Medicine and the San Diego Veterans Administration Medical Center report that human neural stem cells (NSCs) grafted into spinal cord injuries in laboratory rats displayed continued growth and maturity, with functional recovery beginning one year after grafting.
    The findings are published in the September issue of the Journal of Clinical Investigation .
    “The NSCs retained an intrinsic human rate of maturation despite being placed in a traumatic rodent environment,” said Paul Lu, PhD, associate professor of neurosciences and lead author of the study. “That’s a finding of great importance in planning for human clinical trials.”
    Neural stem cells differentiate into neurons and glia or support cells. Researchers like Lu and colleague, Mark Tuszynski, MD, PhD, professor of neuroscience and director of the UC San Diego Translational Neuroscience Institute, have explored their potential as a sort of patch and remedy for spinal cord injuries, implanting NSCs derived from induced pluripotent stem cells into animal models of spinal cord injuries to repair damage. In previously published animal studies, Lu and Tuszynski have shown NSCs can survive implantation and make new connections, even beginning to restore limited physical function, such as foot movement, that had been lost to paralyzing injury.

    more...
    https://health.ucsd.edu/news/release...-injuries.aspx

  8. #908
    spinal cord injury stem cell therapies, rat study suggests
    August 29, 2017 / Todd Dubnicoff
    2017 has been an exciting year for Asterias Biotherapeutics’ clinical trial which is testing a stem cell-based therapy for spinal cord injury. We’ve written several stories about patients who have made remarkable recoveries after participating in the trial (here and here).
    But that doesn’t mean researchers at other companies or institutes who are also investigating spinal cord injury will be closing up shop. There’s still a long way to go with the Asterias trial and there’s still a lot to be learned about the cellular and molecular mechanisms of spinal cord injury repair, which could lead to alternative options for victims. Continued studies will also provide insights on optimizing the methods and data collection used in future clinical trials.

    more...
    https://blog.cirm.ca.gov/2017/08/29/...tudy-suggests/

  9. #909
    Future of You
    Spinal Patients Continue Remarkable Recovery After Stem Cell Injections, Company Says
    By David Gorn
    Future of You October 4, 2017
    ⦁ Patients with spinal injuries have continued to heal long after they’ve received an initial injection of stem cells, ⦁ according to data released Oct. 2 by the biotech company conducting a clinical trial on the treatment.

    read,,,

    https://ww2.kqed.org/futureofyou/201...-company-says/


    Regenerative Medicine Restores Movement After Paralysis

    October 5, 2017
    Twelve-month data from spinal cord injury trial shows two-thirds of subjects recovered two or more motor levels
    /news/press-releases/regenerative-medicine-restores-movement-after-paralysis
    This 67 percent recovery rate is more than double the rates of recovery seen in both matched historical controls and published data in a similar population. Each of the six participants in the study had lost all motor function below the location of the spinal injury.
    They each received a surgical injection of 10 million of the cells being studied. Asterias Biotherapeutics, the biotechnology company that manufactures the cell therapy, reported the 12-month results of the study Oct. 2.
    ‘Vastly better than anything we’ve ever seen before’

    read....
    https://www.rush.edu/news/press-rele...fter-paralysis
    Last edited by manouli; 10-11-2017 at 01:53 PM.

  10. #910
    Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board
    /footer/benefits?tsid=17
    (Ref: GlobeNewswire)
    October 10th, 2017
    ⦁ NEW HAVEN, Conn., Oct. 10, 2017 (GLOBE NEWSWIRE) -- ⦁ ReNetX Bio, a company developing first-in-class therapeutics to treat injury to the central nervous system, is expanding its Scientific Advisory Board with key opinion leaders specializing in spinal cord injury. Andrew Blight, PhD, brings experience as the former Chief Scientific Officer of Acorda Therapeutics, Inc., where he helped move forward therapies for stroke and spinal cord injury (SCI) and ran two of the largest multicenter clinical trials in chronic SCI around the potassium channel blocker, 4-aminopyridine, which achieved FDA approval for the treatment of walking impairment in persons with multiple sclerosis. Blight also brings significant academic research experience, particularly surrounding the role of inflammation and demyelination in SCI, and held faculty roles at New York University Medical Center, Purdue University and the University of North Carolina where he was Professor and Director of the Neurosurgery Research Laboratory.
    ⦁ "I have closely followed the developing science behind ReNetX and I am delighted to see this technology ready to be brought to the clinic for testing in people with spinal cord injury," Blight says.
    read...
    https://www.firstwordpharma.com/node/1512414?tsid=1

Similar Threads

  1. Replies: 0
    Last Post: 08-14-2005, 09:16 AM
  2. New articles posted to Research Forums.
    By Wise Young in forum Cure
    Replies: 1
    Last Post: 04-15-2004, 11:41 AM
  3. Replies: 0
    Last Post: 01-14-2004, 12:00 PM
  4. Replies: 8
    Last Post: 05-15-2003, 02:05 AM
  5. Replies: 1
    Last Post: 05-12-2002, 04:07 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •